Telix Pharmaceuticals Limited ADR (TLX)

$16.71 +0.17 (1.03%)
Market Cap 5.68B
Revenue (ttm) 516.68M
Net Income (ttm) 32.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 41.36
Profit Margin 6.37%
Debt to Equity Ratio 1.00
Volume 8,500
Avg Vol 39,770
Day's Range N/A - N/A
Shares Out 337.88M
Stochastic %K 86%
Beta N/A
Analysts Strong Sell
Price Target $25.00

Latest News on TLX

Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

Apr 16, 2025, 10:57 AM EDT - 2 days ago

Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Apr 15, 2025, 6:37 PM EDT - 3 days ago

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Telix Announces Cardinal Health for Gozellix Commercial Distribution

Apr 8, 2025, 6:30 AM EDT - 11 days ago

Telix Announces Cardinal Health for Gozellix Commercial Distribution

Telix Appoints Paul Schaffer as Chief Technology Officer

Apr 7, 2025, 6:30 AM EDT - 12 days ago

Telix Appoints Paul Schaffer as Chief Technology Officer

Telix Pharmaceuticals: Building A Radiopharma Powerhouse

Apr 5, 2025, 1:03 AM EDT - 14 days ago

Telix Pharmaceuticals: Building A Radiopharma Powerhouse

Anne Whitaker Appointed as Non-Executive Director

Apr 3, 2025, 6:13 PM EDT - 15 days ago

Anne Whitaker Appointed as Non-Executive Director

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

Apr 1, 2025, 3:30 PM EDT - 17 days ago

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®

Apr 1, 2025, 8:49 AM EDT - 18 days ago

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent

Mar 21, 2025, 11:06 AM EDT - 4 weeks ago

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Mar 21, 2025, 6:30 AM EDT - 4 weeks ago

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Mar 17, 2025, 5:53 PM EDT - 4 weeks ago

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Telix Adds Lead-212 Isotope Production Capability

Mar 12, 2025, 6:41 PM EDT - 5 weeks ago

Telix Adds Lead-212 Isotope Production Capability

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

Mar 3, 2025, 4:48 PM EST - 6 weeks ago

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Feb 25, 2025, 6:51 PM EST - 7 weeks ago

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

Feb 25, 2025, 7:30 AM EST - 7 weeks ago

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

Australia's Telix Pharmaceuticals scales record peak on upbeat revenue forecast

Feb 20, 2025, 9:37 PM EST - 2 months ago

Australia's Telix Pharmaceuticals scales record peak on upbeat revenue forecast

Telix Pharmaceuticals Limited (TLPPF) FY 2024 Results Earnings Call Transcript

Feb 20, 2025, 9:29 PM EST - 2 months ago

Telix Pharmaceuticals Limited (TLPPF) FY 2024 Results Earnings Call Transcript

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Feb 20, 2025, 7:10 AM EST - 2 months ago

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Feb 13, 2025, 7:00 AM EST - 2 months ago

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Illuccix® Approved in the United Kingdom

Feb 12, 2025, 4:38 PM EST - 2 months ago

Illuccix® Approved in the United Kingdom

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Jan 30, 2025, 4:57 PM EST - 2 months ago

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Telix Completes Acquisition of RLS (USA) Inc.

Jan 27, 2025, 4:43 PM EST - 2 months ago

Telix Completes Acquisition of RLS (USA) Inc.

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

Jan 22, 2025, 12:55 PM EST - 3 months ago

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

Illuccix® Receives European Approval

Jan 16, 2025, 5:06 PM EST - 3 months ago

Illuccix® Receives European Approval

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 4:35 PM EST - 3 months ago

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Jan 13, 2025, 2:08 AM EST - 3 months ago

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Jan 12, 2025, 5:04 PM EST - 3 months ago

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Dec 30, 2024, 3:45 PM EST - 3 months ago

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Dec 29, 2024, 4:53 PM EST - 3 months ago

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

Nov 18, 2024, 6:20 PM EST - 5 months ago

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

Telix ADSs Commence Trading on Nasdaq

Nov 13, 2024, 4:28 PM EST - 5 months ago

Telix ADSs Commence Trading on Nasdaq